Long-acting Beta-agonists Market size was valued at USD 987.4 million in 2023 and is expected to reach USD 5.67 billion by 2036, expanding at around 14.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of long-acting beta-agonists is evaluated at USD 1.1 billion.
Beta-agonists are bronchodilator medicines that can relax the muscles around the airways and opens the airways, which are tightened during an asthma attack. Long-acting beta-agonists have a longer effect, which is up to 12 hours, as compared to the 4-5 hour effect of the regular beta-agonists. This longer lasting relief provide by the long-acting beta-agonists is estimated to boost their demand amongst the patients of nocturnal asthma, exercise-induced asthma, and COPD (chronic obstructive pulmonary disease). The growth of the market can be attributed to the increasing prevalence of COPD and asthma across the globe. According to the data by the World Health Organization (WHO), COPD is the third leading cause of death worldwide, which caused 3.23 million deaths in 2019. On the other hand, asthma caused 461,000 deaths in 2019, affecting over 262 million people in the same year. Moreover, the advancement in the field of medicine, and increasing demand for chronic respiratory disease treatment, are also estimated to boost the market growth. Apart from this, the prevalence of poor lifestyle, including consumption of tobacco, increased level of pollution, sedentary life, obesity, and higher exposure to allergens, which is leading to respiratory diseases, are also estimated to assist the market growth.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
14.4% |
|
Base Year Market Size (2023) |
USD 987.4 million |
|
Forecast Year Market Size (2036) |
USD 5.67 billion |
|
Regional Scope |
|
The market is segmented by drug type into albuterol, formoterol, salmeterol, and others, out of which, the formoterol segment is anticipated to hold a substantial share in the global long-acting beta-agonists market over the forecast period owing to the longer-lasting action of formoterol-based compositions. Moreover, formoterol is administered as an inhalation powder, which has the maximum relief effect. Such factors are expected to encourage the segment growth.
Our in-depth analysis of the global long-acting beta-agonists market includes the following segments:
|
By Route of Administration |
|
|
By Drug Type |
|
|
By Application |
|
On the basis of geographical analysis, the global long-acting beta-agonists market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is expected to hold largest revenue share by 2036, driven by high prevalence of COPD, bronchospasm, and other disorders amongst the geriatric population. Further, asthma and other respiratory diseases are more common amongst the pediatric and geriatric population. The high population of older adults and children in the APAC region is estimated to boost the market growth.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the high incidences of asthma amongst children. As per the data by the Center for Disease Control and Prevention (CDC), 6 million children below 18 years have asthma, in the U.S.
October, 2020: Astellas Pharma Inc. and Iota Biosciences, Inc. announced a merger agreement, following which, Astellas will acquire Iota’s unique bioelectronics technology.
December 2019: Boston Biomedical, Inc. announced the alliance in oncology research with Columbia University, Harvard University and The Wistar Institute, the three world-leading oncology centers of excellence.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?